Stålhammar Gustav, Yeung Aaron, Mendoza Pia, Dubovy Sander R, William Harbour J, Grossniklaus Hans E
Ocular Pathology Service, St. Erik Eye Hospital, Stockholm, Sweden.
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Ophthalmol Sci. 2021 Dec 11;2(1):100089. doi: 10.1016/j.xops.2021.100089. eCollection 2022 Mar.
Gain of chromosome 6p has been associated with poor ocular survival in retinoblastoma and histopathologic grading of anaplasia with increased risk of metastatic spread and death. This study examined the correlation between these factors and other chromosomal abnormalities as well as results of whole genome sequencing, digital morphometry, and progression-free survival.
Retrospective cohort study from 2 United States tertiary referral centers.
Forty-two children who had undergone enucleation for retinoblastoma from January 2000 through December 2017.
Status of chromosomes 6p, 1q, 9q, and 16q was evaluated with fluorescence in situ hybridization, the degree of anaplasia and presence of histologic high-risk features were assessed by ocular pathologists, digital morphometry was performed on scanned tumor slides, and whole genome sequencing was performed on a subset of tumors. Progression-free survival was defined as absence of distant or local metastases or tumor growth beyond the cut end of the optic nerve.
Correlation between each of chromosomal abnormalities, anaplasia, morphometry and sequencing results, and survival.
Forty-one of 42 included patients underwent primary enucleation and 1 was treated first with intra-arterial chemotherapy. Seven tumors showed mild anaplasia, 19 showed moderate anaplasia, and 16 showed severe anaplasia. All tumors had gain of 1q, 18 tumors had gain of 6p, 6 tumors had gain of 9q, and 36 tumors had loss of 16q. Tumors with severe anaplasia were significantly more likely to harbor 6p gains than tumors with nonsevere anaplasia ( < 0.001). Further, the hematoxylin staining intensity was significantly greater and that of eosin staining significantly lower in tumors with severe anaplasia ( < 0.05). Neither severe anaplasia ( = 0.10) nor gain of 6p ( = 0.21) correlated with histologic high-risk features, and severe anaplasia did not correlate to , , , or mutations in a subset of 14 tumors ( > 0.5). Patients with gain of 6p showed significantly shorter progression-free survival ( = 0.03, Wilcoxon test).
Gain of chromosome 6p emerges as a strong prognostic biomarker in retinoblastoma because it correlates with severe anaplasia, quantifiable changes in tumor cell staining characteristics, and extraocular spread.
6号染色体短臂(6p)的获得与视网膜母细胞瘤患者较差的眼部生存率、间变的组织病理学分级相关,且转移扩散和死亡风险增加。本研究探讨了这些因素与其他染色体异常之间的相关性,以及全基因组测序、数字形态测量和无进展生存期的结果。
来自美国2家三级转诊中心的回顾性队列研究。
2000年1月至2017年12月期间因视网膜母细胞瘤接受眼球摘除术的42名儿童。
采用荧光原位杂交技术评估6p、1q、9q和16q染色体状态,由眼科病理学家评估间变程度和组织学高危特征的存在情况,对扫描的肿瘤切片进行数字形态测量,并对部分肿瘤进行全基因组测序。无进展生存期定义为无远处或局部转移,或肿瘤生长未超过视神经断端。
各染色体异常、间变、形态测量和测序结果与生存率之间的相关性。
42例纳入患者中,41例接受了初次眼球摘除术,1例首先接受动脉内化疗。7例肿瘤表现为轻度间变,19例表现为中度间变,16例表现为重度间变。所有肿瘤均有1q获得,18例肿瘤有6p获得,6例肿瘤有9q获得,36例肿瘤有16q缺失。与非重度间变的肿瘤相比,重度间变的肿瘤更有可能出现6p获得(<0.001)。此外,重度间变的肿瘤苏木精染色强度显著更高,伊红染色强度显著更低(<0.05)。重度间变(=0.10)和6p获得(=0.21)均与组织学高危特征无关,在14例肿瘤的亚组中,重度间变与、、、或突变无关(>0.5)。6p获得的患者无进展生存期显著缩短(=0.03,Wilcoxon检验)。
6号染色体短臂(6p)的获得是视网膜母细胞瘤中一个强有力的预后生物标志物,因为它与重度间变、肿瘤细胞染色特征的可量化变化以及眼外扩散相关。